Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review

Novartis AG (NOVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by it to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections among others. The company offers eye care products through its subsidiary, Alcon; and generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices in the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG Key Recent Developments

Feb 11,2019 Recro Pharma announces five-year manufacturing and supply agreement between Novartis and Recro Gainesville
Jan 30,2019 Aduro Biotech announces strategic reset
Jan 28,2019 Novartis stockpiles medicines ahead of Brexit
Jan 21,2019 Novartis chooses Kinaxis technology to improve supply chain planning

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


List of Tables
List of Figures
Section 1 - About the Company
Novartis AG - Key Facts
Novartis AG - Key Employees
Novartis AG - Key Employee Biographies
Novartis AG - Major Products and Services
Novartis AG - History
Novartis AG - Company Statement
Novartis AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 Company Analysis
Company Overview
Novartis AG - Business Description
Business Segment: Alcon
Overview
Performance
Key Stats
Business Segment: Innovative Medicines
Overview
Performance
Key Stats
Business Segment: Sandoz
Overview
Performance
Key Stats
Geographical Segment: Americas
Target Markets
Performance
Geographical Segment: Asia/Africa/Australasia
Performance
Geographical Segment: Europe
Target Markets
Performance
R&D Overview
Novartis AG - Corporate Strategy
Novartis AG - SWOT Analysis
SWOT Analysis - Overview
Novartis AG - Strengths
Novartis AG - Weaknesses
Novartis AG - Opportunities
Novartis AG - Threats
Novartis AG - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Novartis AG, Recent Deals Summary
Section 5 Companys Recent Developments
Feb 11, 2019: Recro Pharma announces five-year manufacturing and supply agreement between Novartis and Recro Gainesville
Jan 30, 2019: Aduro Biotech announces strategic reset
Jan 28, 2019: Novartis stockpiles medicines ahead of Brexit
Jan 21, 2019: Novartis chooses Kinaxis technology to improve supply chain planning
Jan 18, 2019: Novartis and University of Oxford partner on AI-based drug development
Jan 10, 2019: Novartis response to NICE Appraisal Consultation Document (ACD) for Aimovig&174; (erenumab) for the prevention of migraine
Jan 09, 2019: Adimab provides 2018 update on clinical pipeline
Jan 08, 2019: Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
Dec 21, 2018: Novartis makes offer to acquire French CDMO CellforCure
Dec 20, 2018: Novartis announces new CEO of Oncology Business Unit
Section 6 Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables


Novartis AG, Key Facts
Novartis AG, Key Employees
Novartis AG, Key Employee Biographies
Novartis AG, Major Products and Services
Novartis AG, History
Novartis AG, Subsidiaries
Novartis AG, Key Competitors
Novartis AG, Ratios based on current share price
Novartis AG, Annual Ratios
Novartis AG, Annual Ratios (Cont...1)
Novartis AG, Annual Ratios (Cont...2)
Novartis AG, Interim Ratios
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Novartis AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Novartis AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures


Novartis AG, Performance Chart (2014 - 2018)
Novartis AG, Ratio Charts
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

Enterprise Tech Ecosystem Series - Novartis AG

Enterprise Tech Ecosystem Series - Novartis AG market research report available in single user pdf license with Aarkstore Enterprise at USD 1295

USD 1295 View Report

Novartis AG in Eyewear (World)

Novartis ranks second in the global contact lenses and solutions market. The company has established a strong foothold in North America and Western Europe, and is continuing to grow its

USD 572 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available